Estimating Cancer Screening Sensitivity and Specificity Using Healthcare Utilization Data: Defining the Accuracy Assessment Interval.
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
02 08 2022
02 08 2022
Historique:
received:
02
03
2022
revised:
29
04
2022
accepted:
23
05
2022
entrez:
2
8
2022
pubmed:
3
8
2022
medline:
5
8
2022
Statut:
ppublish
Résumé
The effectiveness and efficiency of cancer screening in real-world settings depend on many factors, including test sensitivity and specificity. Outside of select experimental studies, not everyone receives a gold standard test that can serve as a comparator in estimating screening test accuracy. Thus, many studies of screening test accuracy use the passage of time to infer whether or not cancer was present at the time of the screening test, particularly for patients with a negative screening test. We define the accuracy assessment interval as the period of time after a screening test that is used to estimate the test's accuracy. We describe how the length of this interval may bias sensitivity and specificity estimates. We call for future research to quantify bias and uncertainty in accuracy estimates and to provide guidance on setting accuracy assessment interval lengths for different cancers and screening modalities.
Identifiants
pubmed: 35916602
pii: 707142
doi: 10.1158/1055-9965.EPI-22-0232
pmc: PMC9484579
mid: NIHMS1829440
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1517-1520Subventions
Organisme : NCI NIH HHS
ID : UM1 CA221939
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA221940
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA167540
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA222035
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA221936
Pays : United States
Informations de copyright
©2022 American Association for Cancer Research.
Références
J Med Screen. 2010;17(3):132-8
pubmed: 20956723
BMC Med Res Methodol. 2009 Jan 20;9:4
pubmed: 19154609
BMC Med Res Methodol. 2021 Apr 12;21(1):67
pubmed: 33845775
Breast. 2009 Jun;18(3):208-10
pubmed: 19359176
BMJ Evid Based Med. 2018 Apr;23(2):54-55
pubmed: 29595130
J Gen Intern Med. 2010 Nov;25(11):1211-21
pubmed: 20499198
Ann Intern Med. 1990 Mar 1;112(5):328-33
pubmed: 2407166
Int J Cancer. 2006 Jan 1;118(1):174-9
pubmed: 16003756
J Med Screen. 2009;16(1):39-45
pubmed: 19349530
Br J Radiol. 2012 Dec;85(1020):e1226-32
pubmed: 22993383
JAMA. 2016 Jun 21;315(23):2576-94
pubmed: 27305422
J Med Screen. 2017 Sep;24(3):146-152
pubmed: 28142309
Biostatistics. 2001 Sep;2(3):249-60
pubmed: 12933537
Stat Med. 2011 Jul 10;30(15):1852-64
pubmed: 21495059
J Med Screen. 2007;14(4):174-7
pubmed: 18078561